122 related articles for article (PubMed ID: 38326875)
1. IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy.
Tanner G; Barrow R; Ajaib S; Al-Jabri M; Ahmed N; Pollock S; Finetti M; Rippaus N; Bruns AF; Syed K; Poulter JA; Matthews L; Hughes T; Wilson E; Johnson C; Varn FS; Brüning-Richardson A; Hogg C; Droop A; Gusnanto A; Care MA; Cutillo L; Westhead DR; Short SC; Jenkinson MD; Brodbelt A; Chakrabarty A; Ismail A; Verhaak RGW; Stead LF
Genome Biol; 2024 Feb; 25(1):45. PubMed ID: 38326875
[TBL] [Abstract][Full Text] [Related]
2. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment.
Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH
EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
4. Current Insights into Mesenchymal Signatures in Glioblastoma.
Matsumoto Y; Ichikawa T; Kurozumi K; Date I
Acta Med Okayama; 2022 Oct; 76(5):489-502. PubMed ID: 36352795
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
Steponaitis G; Tamasauskas A
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
[TBL] [Abstract][Full Text] [Related]
6. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
7. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance.
Kwon SM; Kang SH; Park CK; Jung S; Park ES; Lee JS; Kim SH; Woo HG
PLoS One; 2015; 10(10):e0140528. PubMed ID: 26466313
[TBL] [Abstract][Full Text] [Related]
9. Clonal ZEB1-Driven Mesenchymal Transition Promotes Targetable Oncologic Antiangiogenic Therapy Resistance.
Chandra A; Jahangiri A; Chen W; Nguyen AT; Yagnik G; Pereira MP; Jain S; Garcia JH; Shah SS; Wadhwa H; Joshi RS; Weiss J; Wolf KJ; Lin JG; Müller S; Rick JW; Diaz AA; Gilbert LA; Kumar S; Aghi MK
Cancer Res; 2020 Apr; 80(7):1498-1511. PubMed ID: 32041837
[TBL] [Abstract][Full Text] [Related]
10. Nuclear respiratory factor 1 transcriptomic signatures as prognostic indicators of recurring aggressive mesenchymal glioblastoma and resistance to therapy in White American females.
Bhawe K; Das JK; Yoo C; Felty Q; Gong Z; Deoraj A; Liuzzi JP; Ehtesham NZ; Hasnain SE; Singh VP; Mohapatra I; Komotar RJ; Roy D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1641-1682. PubMed ID: 35441887
[TBL] [Abstract][Full Text] [Related]
11. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
13. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
He X; Zhang S; Chen J; Li D
Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
[TBL] [Abstract][Full Text] [Related]
14. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
15. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.
Jeon H; Byun J; Kang H; Kim K; Lee E; Kim JH; Hong CK; Song SW; Kim YH; Chong S; Kim JH; Nam SJ; Park JE; Lee S
J Transl Med; 2023 Feb; 21(1):69. PubMed ID: 36732815
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.
Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH
OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679
[TBL] [Abstract][Full Text] [Related]
18. GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data.
Ajaib S; Lodha D; Pollock S; Hemmings G; Finetti MA; Gusnanto A; Chakrabarty A; Ismail A; Wilson E; Varn FS; Hunter B; Filby A; Brockman AA; McDonald D; Verhaak RGW; Ihrie RA; Stead LF
Neuro Oncol; 2023 Jul; 25(7):1236-1248. PubMed ID: 36689332
[TBL] [Abstract][Full Text] [Related]
19. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
20. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
